- Patients
- Clinical Research
- Clinical trials
- SEAMARK
Colorectal Cancer
SEAMARK – C4221022
Phase 2, randomized, open-label study of encorafenib and cetuximab plus pembrolizumab versus pembrolizumab alone in participants with previously untreated BRAF V600E-mutant, MSI H/DMMR metastatic colorectal cancer.
Trial overview
Medical Oncology
Colorectal
II
Registration number: NCT05217446
North Shore
North Shore Health Hub, Tower A, Level 1, 7 Westbourne St, St Leonards, NSW, 2065, Australia
(02) 8037 4100 admin.northshore@genesiscare.comMedical Oncologist
A/Prof. Connie Diakos
BSc (Hons) PhD MBBS FRACP
Frenchs Forest (Oncology) +1
Disclaimer:
This website is provided for information purposes only. Nothing on this website is intended to be used as medical advice, or to diagnose, treat, cure or prevent any disease. It should not be used as a substitute for your own health professional's advice. Any medical procedure or treatment carries risks. Before proceeding with treatment, you should discuss the risks and benefits of the treatment with an appropriately qualified health practitioner. Individual treatment outcomes and experiences will vary.